2 October 2024

Howe Street Reporter Title

Category: Psychedelics

  • Lophos Holdings (MESC.C) is selling peyote soon, and you didn’t even know

    Lophos Holdings (MESC.C) is selling peyote soon, and you didn’t even know

    Lophos Holdings (MESC.C) is a Canadian public company – the only public company – specifically focused on the quickly liberalizing psychedelics sub-sector of Peyote and Mescaline. You may be sitting back in your chair now thinking, “Well hello there,” and I’m with you. For most of my life, peyote was a thing we did with…

  • Revive Therapeutics (RVV.C) licenses patent on long COVID biomarkers

    Revive Therapeutics (RVV.C) licenses patent on long COVID biomarkers

    Revive Therapeutics (RVV.C), a company that specializes in creating treatments and tests for diseases that don’t have many existing options available, has made a deal with a health research group called Lawson Health Research Institute to license the rights  to use special signals in the blood—called biomarkers—that can show if someone has ‘long COVID.’ “We…

  • Private med reformulator SecureDose acquired by PharmaDrug Inc (PHRX.C)

    Private med reformulator SecureDose acquired by PharmaDrug Inc (PHRX.C)

    A few weeks back, in what has become a seminal Equity.Guru piece about the quickly legalizing safe supply drug space, I tore into PharmaDrug (PHRX.C), which was lurching into strategic alternatives land as it appeared to have run out of dough to push its drug trials forward. Pharmadrug (PHRX.C) would love to be in the cocaine…

  • Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting

    Revive Therapeutics (RVV.C): Covid came, Covid went, but Revive is still fighting

    Back at the dawn of Covid-19, a load of public companies started pumping out news releases that claimed they were going to be entering the medical space. In the best tradition of Howe Street, long dormant mining companies suddenly became med-tech deals, hawking everything from clear plastic checkout counter dividers to virus sniffing doorways to…

  • Multi-Company Wrap: Watching the watchlist so you don’t have to

    Multi-Company Wrap: Watching the watchlist so you don’t have to

    We have some 29 companies on our watchlist, all in a variety of sectors, that we’re covering at any one time. Some are clients, some not, some are on deaths door, some are skyrocketing, so we’ve decided to wrap them all up into one monthly wrap so you can keep track of everything at once.…

  • Pubco cocaine is here: What does it mean, who’s in, and who’s real?

    Pubco cocaine is here: What does it mean, who’s in, and who’s real?

    I recently listened to a podcast episode of Search Engine with PJ Vogt, and I REALLY got into it. The episode was titled, “Why are drug dealers putting fentanyl in everything?” I’d asked myself the same question many times – why kill your customers? I’d recommend you go listen because the answer is a lot…

  • Today’s Idea: Filament Health’s (FH.NE) psychedelics play

    Today’s Idea: Filament Health’s (FH.NE) psychedelics play

    Our Psychedelic Trip Isn’t Over I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector was experiencing an unprecedented breakout period. Maybe it was because of mainstream media or perhaps it was my nagging parents, but I have always feared psychedelics. Back…

  • Today’s Idea: Filament Health (FH.NE) Is All Natural

    Today’s Idea: Filament Health (FH.NE) Is All Natural

    Natural Talent Albert Hofmann was a fun guy, pun intended. More importantly, the Swiss chemist is known for being the first person to synthesize, consume, and learn of the psychedelic effects of lysergic acid diethylamide (LSD). Truly a mad chemist. Furthermore, Hofmann was also the first person to isolate, synthesize, and name the principal psychedelic compounds…

  • Mydecine Innovations (MYCO.NEO) is operating on the leading edge of mental health & addiction treatment

    Mydecine Innovations (MYCO.NEO) is operating on the leading edge of mental health & addiction treatment

    On February 16, 2022 Mydecine Innovations Group (MYCO.NEO) announced the inclusion of a novel molecule with potentially heart-safe microdose enabling properties in their family of psilocin analogs. Founded in 2020, Mydecine Innovations is a biotechnology company developing therapeutics to treat unmet needs in mental health and addiction disorders. Focusing on psychedelic compounds with therapeutic potential,…

  • Today’s Idea: Filament Health (FH.NE) Gaining Traction

    Today’s Idea: Filament Health (FH.NE) Gaining Traction

    Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple peer-reviewed studies, I adamantly believed psychedelics would melt your brain. In retrospect, that belief is just about as bogus as going to hell for premarital hand-holding.…